New and Emerging Therapies for Pediatric Atopic Dermatitis

Henry L. Nguyen, Katelyn R. Anderson, Megha M Tollefson

Research output: Contribution to journalReview article

Abstract

Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.

Original languageEnglish (US)
Pages (from-to)239-260
Number of pages22
JournalPediatric Drugs
Volume21
Issue number4
DOIs
StatePublished - Aug 1 2019

Fingerprint

Atopic Dermatitis
Pediatrics
Emollients
Aryl Hydrocarbon Receptors
Skin
Interleukin-13
Therapeutics
Pruritus
Immunosuppressive Agents
Skin Diseases
Interleukin-4
Action Potentials
Steroids
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

New and Emerging Therapies for Pediatric Atopic Dermatitis. / Nguyen, Henry L.; Anderson, Katelyn R.; Tollefson, Megha M.

In: Pediatric Drugs, Vol. 21, No. 4, 01.08.2019, p. 239-260.

Research output: Contribution to journalReview article

Nguyen, Henry L. ; Anderson, Katelyn R. ; Tollefson, Megha M. / New and Emerging Therapies for Pediatric Atopic Dermatitis. In: Pediatric Drugs. 2019 ; Vol. 21, No. 4. pp. 239-260.
@article{f82d8144836947fc8c907484ec372da1,
title = "New and Emerging Therapies for Pediatric Atopic Dermatitis",
abstract = "Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.",
author = "Nguyen, {Henry L.} and Anderson, {Katelyn R.} and Tollefson, {Megha M}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s40272-019-00342-w",
language = "English (US)",
volume = "21",
pages = "239--260",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - New and Emerging Therapies for Pediatric Atopic Dermatitis

AU - Nguyen, Henry L.

AU - Anderson, Katelyn R.

AU - Tollefson, Megha M

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.

AB - Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.

UR - http://www.scopus.com/inward/record.url?scp=85070342323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070342323&partnerID=8YFLogxK

U2 - 10.1007/s40272-019-00342-w

DO - 10.1007/s40272-019-00342-w

M3 - Review article

VL - 21

SP - 239

EP - 260

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 4

ER -